- Reaction score
- 34
DHT serum concentrations
After 24 wk of treatment, suppression of DHT was ob-served with a clear dose-response curve for percent changefrom baseline for the dutasteride treatment groups (Fig. 1).
Adjusted mean - sd decreases in DHT from baseline for the dutasteride treatment groups were as follows:
98.4 - 1.2% (5.0 mg);
97.7 - 2.0% (2.5 mg);
94.7 - 3.3% (0.5 mg);
52.9 - 22.1% (0.05 mg); and
7.5 - 26.6% (0.01 mg).
Of note is the reduction in variability (sd bars) with increase in dutasteride
dose. In comparison, the adjusted mean decrease in DHT with finasteride was
70.8 - 18.3%.
The percent changes in DHT from baseline for dutasteride doses of 0.5, 2.5, and 5.0
mg were significantly greater than placebo (P 0.001) and finasteride (P 0.001).
The percentage of patients with DHT levels less than 10 pg/ml at the end of the 24-wk drug exposure was 10% in the 0.5-mg dutasteride group, 64% in the 2.5-mg dutasteride
group, and 75% in the 5.0-mg dutasteride group.
In the finasteride group, no subject had a DHT level less than 10 pg/ml, and only 9% had a DHT level less than 50 pg/ml.
As the dutasteride dose increased, the variability of the response decreased from a sd of 22.1% with dutasteride at 0.05 mg to
a sd of 1.2% with dutasteride at 5.0 mg.
The time courses of the changes in mean percent DHT levels for the different treatment groups during the study are
shown in Fig. 2.
Mean percent DHT levels returned to within
20% of baseline with dutasteride at 0.05 mg and finasteride
at wk 4 post treatment
For dutasteride at 0.5 mg at wk
16 post treatment.
With the highest doses of dutasteride, 2.5
and 5.0 mg, the mean percent DHT levels remained suppressed by 85% or more from baseline at 16 wk post treatment.
https://academic.oup.com/jcem/article/89/5/2179/2844345
After 24 wk of treatment, suppression of DHT was ob-served with a clear dose-response curve for percent changefrom baseline for the dutasteride treatment groups (Fig. 1).
Adjusted mean - sd decreases in DHT from baseline for the dutasteride treatment groups were as follows:
98.4 - 1.2% (5.0 mg);
97.7 - 2.0% (2.5 mg);
94.7 - 3.3% (0.5 mg);
52.9 - 22.1% (0.05 mg); and
7.5 - 26.6% (0.01 mg).
Of note is the reduction in variability (sd bars) with increase in dutasteride
dose. In comparison, the adjusted mean decrease in DHT with finasteride was
70.8 - 18.3%.
The percent changes in DHT from baseline for dutasteride doses of 0.5, 2.5, and 5.0
mg were significantly greater than placebo (P 0.001) and finasteride (P 0.001).
The percentage of patients with DHT levels less than 10 pg/ml at the end of the 24-wk drug exposure was 10% in the 0.5-mg dutasteride group, 64% in the 2.5-mg dutasteride
group, and 75% in the 5.0-mg dutasteride group.
In the finasteride group, no subject had a DHT level less than 10 pg/ml, and only 9% had a DHT level less than 50 pg/ml.
As the dutasteride dose increased, the variability of the response decreased from a sd of 22.1% with dutasteride at 0.05 mg to
a sd of 1.2% with dutasteride at 5.0 mg.
The time courses of the changes in mean percent DHT levels for the different treatment groups during the study are
shown in Fig. 2.
Mean percent DHT levels returned to within
20% of baseline with dutasteride at 0.05 mg and finasteride
at wk 4 post treatment
For dutasteride at 0.5 mg at wk
16 post treatment.
With the highest doses of dutasteride, 2.5
and 5.0 mg, the mean percent DHT levels remained suppressed by 85% or more from baseline at 16 wk post treatment.
https://academic.oup.com/jcem/article/89/5/2179/2844345
.